Trichomoniasis Market

• The trichomoniasis market is anticipated to sustain a steady Compound Annual Growth Rate (CAGR) during the forecast period (2025-2034). This growth in market revenue is primarily propelled by advancements in diagnostic techniques, heightened awareness of the condition, and a growing number of reported cases. 
• The trichomoniasis cases are increasing due to limited awareness, lack of routine screening, and high rates of asymptomatic infections that go undiagnosed. Inconsistent partner treatment and rising drug tolerance further contribute to ongoing transmission. Additionally, surveillance gaps hinder timely identification and control.
• Lupin’s SOLOSEC (secnidazole) is the only US FDA-approved therapy for trichomoniasis, addressing a key unmet need with its single-dose oral regimen that improves adherence and outcomes. As the most common non-viral STI in the US—especially among underserved populations—trichomoniasis has long lacked an approved, convenient treatment.
• There is a pressing need for alternative therapies to address metronidazole-resistant Trichomonas Vaginalis, as current treatment options are few and often ineffective against strains with reduced sensitivity. Standard diagnostic methods may fail to detect emerging resistance, making it difficult to guide appropriate therapy and increasing the risk of persistent infection and transmission. Developing new agents with novel mechanisms of action is essential to overcome these limitations and improve patient outcomes.
• The absence of emerging drugs for trichomoniasis is largely due to limited market potential, low public health prioritization, and the perception that existing treatments are sufficient, which discourages investment in research and development for novel therapies. 

DelveInsight’s comprehensive report titled “Trichomoniasis — Market Insights, Epidemiology, and Market Forecast – 2034” offers a detailed analysis of trichomoniasis. The report presents historical and projected epidemiological data covering total prevalent cases of trichomoniasis, total diagnosed prevalent cases of trichomoniasis, gender-specific diagnosed prevalent cases of trichomoniasis and age-specific diagnosed prevalent cases of trichomoniasis. In addition to epidemiology, the market report encompasses various aspects related to the patient population. These aspects include the diagnosis process, prescription patterns, physician perspectives, market accessibility, treatment options, and prospective developments in the market across seven major markets: the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, spanning from 2020 to 2034.

The report analyzes the existing treatment practices and unmet medical requirements in trichomoniasis. It evaluates the market potential and identifies potential business prospects for enhancing therapies or interventions. This valuable information enables stakeholders to make well-informed decisions regarding product development and strategic planning for the market.

Trichomoniasis Overview

Trichomoniasis is a common sexually transmitted infection caused by the protozoan Trichomonas vaginalis. It is the most widespread nonviral Sexually Transmitted Infection (STI) globally, affecting millions of individuals, yet it often goes undiagnosed since most people do not experience any symptoms.

The parasite spreads through sexual contact via infected semen, vaginal fluids, or direct genital skin-to-skin contact. Its ability to spread widely is largely due to the fact that many individuals do not experience symptoms and unknowingly transmit the infection to their partners.

Women tend to exhibit more noticeable symptoms than men. When symptoms occur, they may include a thin, sometimes frothy vaginal discharge with a foul odor and discomfort in the genital area. Men, on the other hand, usually experience few, if any, symptoms, which further contributes to the silent spread of the infection.

Beyond the immediate discomfort, untreated trichomoniasis can lead to more serious complications. In women, the infection is linked to an increased risk of pelvic inflammatory disease, infertility, and adverse pregnancy outcomes such as preterm birth or low birth weight. Additionally, there is an elevated risk for acquiring and transmitting HIV among infected individuals.

Understanding these aspects of trichomoniasis underscores the public health significance of the infection, especially given its high prevalence and the large number of asymptomatic cases.

Trichomoniasis Diagnosis and Treatment Algorithm 

Trichomoniasis is typically diagnosed through a combination of a physical exam and laboratory testing. During the clinical evaluation, a healthcare provider may perform a pelvic exam (for women) or a genital exam (for men) and collect a sample of vaginal or penile discharge using a cotton swab. Visual cues, such as a “strawberry cervix” in women, can suggest the infection, but the definitive diagnosis is made by examining the specimen under a microscope. If the parasite isn’t immediately visible, the sample may be sent to a laboratory for further evaluation with culture techniques or nucleic acid amplification tests. Providers often recommend testing for other sexually transmitted infections since co-infections can occur.

Trichomoniasis is treated with oral antibiotics—commonly metronidazole or tinidazole—which effectively eliminate the parasite. Women are usually prescribed a seven-day course, whereas a single dose often suffices for men. It is crucial that all sexual partners are treated simultaneously to prevent reinfection, and individuals are advised to abstain from sexual activity for at least one week after completing therapy. For prevention, consistent condom use, routine screening for sexually transmitted infections, and open communication with sexual partners are recommended strategies. Early detection and prompt treatment are essential to mitigate the spread and potential complications of the infection.

Trichomoniasis Epidemiology

The epidemiology section of the trichomoniasis market report offers information on the patient populations, including historical and projected trends for each of the seven major markets. Examining key opinion leader views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The diagnosed patient pool, their trends, and the underlying assumptions are all included in this section of the report.

This section also presents the data with relevant tables and graphs, offering a clear and concise view of the prevalence of trichomoniasis. Additionally, the report discloses the assumptions made during the analysis, ensuring data interpretation and presentation transparency. This epidemiological data is valuable for understanding the disease burden and its impact on the patient population across various regions.

Key Findings

According to the secondary analysis, trichomoniasis is the most prevalent nonviral STI globally, with an estimated 2.6 million cases in the US. Because it is not a reportable condition and lacks universal screening recommendations, current prevalence data are largely derived from population-based and clinic-based studies.

As per the research study, the estimated prevalence of Trichomonas vaginalis infection in the US population-based data is higher in females than males, with rates at 2.1% and 0.5% respectively. Symptomatic individuals are found to have a greater likelihood of infection compared to those without symptoms.

In Europe, the prevalence of Trichomonas vaginalis was low across all testing sites, with 0.8% of male samples and 1.3% of female samples testing positive. Most of these cases were identified in individuals attending primary care or STI clinics. Rectal swab samples showed slightly higher prevalence rates—1.4% in males and 3.5% in females—though these differences were not statistically significant.

As per the analysis, the estimated prevalence of Trichomonas vaginalis in the UK between 2010 and 2012 among individuals aged 16–44 years with at least one lifetime sexual partner was 0.3% in females, while no infections were identified in males based on urine sample testing.

In France, Trichomonas vaginalis infections were most commonly reported among individuals aged 16 to 24 years, accounting for 45.1% of cases, followed by 33.9% in those aged 25 to 34 years. The 35 to 44 years group represented 14.2% of cases, while individuals over 45 years accounted for 6.3%. Only 0.5% of cases were reported in those under 16 years.

In Japan, the prevalence of Trichomonas vaginalis among women was found to be 4.2%. More than half of the individuals who tested positive were asymptomatic, highlighting the likelihood of undetected and ongoing transmission.

The epidemiology of trichomoniasis is expected to change during the forecast period (2025-2034).

Trichomoniasis Market Outlook

The trichomoniasis therapeutics market is further expected to increase by the major drivers, such as the rising prevalent population, technological advancements, and upcoming therapies in the forecast period [2025–2034].

In July 2021, the US FDA approved Lupin’s supplemental New Drug Application (NDA) expanding SOLOSEC (secnidazole) to include treatment of trichomoniasis in adults, following Phase III data showing a 92.2% cure rate. This approval was further extended in February 2022 to include adolescents aged 12 years and older for both trichomoniasis and bacterial vaginosis, reinforcing SOLOSEC’s position as the first and only single-dose oral antimicrobial approved for both infections. In September 2017, the US FDA approved Symbiomix Therapeutics’ SOLOSEC oral granules for the treatment of bacterial vaginosis in adult women.

With ongoing research and continued commitment, the outlook remains positive for enhancing current therapies and ensuring broader access to effective, curative treatment. According to DelveInsight, the trichomoniasis market in the 7MM is expected to change significantly during the study period 2020–2034.

Trichomoniasis Recent Developments

• In August 2025, Evofem Biosciences, Inc. (OTCID: EVFM) announced that a newly issued U.S. patent covering SOLOSEC® (secnidazole) 2 g oral granules and one of its labeled indications has been listed in the U.S. Food and Drug Administration (FDA) publication Approved Drug Products with Therapeutic Equivalence Evaluations (the Orange Book).

Trichomoniasis Drug Chapters 

Marketed Trichomoniasis Drugs

SOLOSEC (secnidazole): Lupin

SOLOSEC (secnidazole) 2g oral granules is the first and only single-dose oral prescription treatment approved for both bacterial vaginosis in females aged 12 and older and trichomoniasis in patients aged 12 and older. The formulation is designed for convenience, with one oral dose providing a complete course of treatment, simplifying management and improving adherence.

As an antimicrobial agent, SOLOSEC offers dual-action coverage against two common infections. For trichomoniasis, which is sexually transmitted, it is essential that sexual partners are treated simultaneously with the same dose to prevent reinfection and support effective disease control.

In October 2017, Lupin acquired Symbiomix Therapeutics, adding the newly approved SOLOSEC for bacterial vaginosis to its women’s healthcare portfolio.

Note: Detailed marketed therapies assessment will be provided in the final report.

Trichomoniasis Market Segmentation

DelveInsight’s ‘Trichomoniasis – Market Insights, Epidemiology, and Market Forecast – 2034’ report provides a detailed outlook of the current and future trichomoniasis market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies. 

Trichomoniasis Market Size by Countries

The trichomoniasis market size is assessed separately for various countries, including the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. In 2024, the United States held a significant share of the overall 7MM (Seven Major Markets) trichomoniasis market, primarily attributed to the country’s higher prevalence of the condition and the elevated cost of the available treatments. This dominance is projected to persist, especially with the potential early introduction of new products.  

Note: Detailed market segment assessment will be provided in the final report.

Trichomoniasis Market Access and Reimbursement

DelveInsight’s ‘Trichomoniasis – Market Insights, Epidemiology, and Market Forecast – 2034’ report provides a descriptive overview of the market access and reimbursement scenario of trichomoniasis.

This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments. 

KOL Views

To keep up with current trichomoniasis market trends and fill gaps in secondary findings, we interview KOLs and SMEs’ working in the trichomoniasis domain. Their opinion helps understand and validate current and emerging therapies and treatment patterns or trichomoniasis market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the trichomoniasis unmet needs.

Trichomoniasis: KOL Insights

DelveInsight’s analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as University of Alabama, US, Hämostaseologie, Humangenetik und Mikrobiologie, Germany, University Hospital of Wales, UK, Hospital Universitario Clínico San Cecilio, Spain, and Keio University School of Medicine in Japan, among others. 

“Trichomoniasis is a highly prevalent and curable sexually transmitted infection that continues to be under recognized in clinical settings. Its asymptomatic nature in many individuals and lack of routine screening contribute to ongoing transmission and missed diagnoses. Emerging diagnostic technologies offer promise, but greater clinical awareness and targeted testing remain essential for effective management.”

“Trichomonas vaginalis remains a persistent challenge due to its high transmission potential, frequent lack of symptoms, and association with adverse reproductive and sexual health outcomes. Its burden is often overlooked, yet it contributes to complications that extend far beyond initial infection.”

“Trichomoniasis remains under recognized in Japan, yet its burden may rival other major sexually transmitted infections. The frequent co-infection with human papillomavirus raises concerns about broader reproductive health risks. Standard drug resistance testing may miss early signs of reduced metronidazole sensitivity, pointing to the need for better diagnostics and the development of alternative treatments.”

Note: Detailed assessment of KOL Views will be provided in the full report on trichomoniasis.

Competitive Intelligence Analysis

We conduct a Competitive and Market Intelligence analysis of the trichomoniasis Market, utilizing various Competitive Intelligence tools such as SWOT analysis and Market entry strategies. The inclusion of these analyses is contingent upon data availability, ensuring a comprehensive and well-informed assessment of the market landscape and competitive dynamics.

Trichomoniasis Report Insights

• Trichomoniasis Patient Population
• Therapeutic Approaches
• Trichomoniasis Drug Analysis
• Trichomoniasis Market Size and Trends
• Trichomoniasis Market Opportunities
• Impact of Upcoming Therapies

Trichomoniasis Report Key Strengths

• 10 Years Forecast
• The 7MM Coverage
• Trichomoniasis Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Trichomoniasis Market
• Trichomoniasis Drugs Uptake

Trichomoniasis Report Assessment

• Trichomoniasis Current Treatment Practices
• Unmet Needs
• Trichomoniasis Pipeline Product Profiles
• Trichomoniasis Market Attractiveness

Key Questions

• How common is trichomoniasis?
• What are the key findings of trichomoniasis epidemiology across the 7MM, and which country will have the highest number of patients during the study period (2020–2034)?
• What are the currently available treatments for trichomoniasis?
• What are the disease risk, burden, and unmet needs of trichomoniasis?
• At what CAGR is the trichomoniasis market and its epidemiology is expected to grow in the 7MM during the forecast period (2025–2034)?
• How would the unmet needs impact the trichomoniasis market dynamics and subsequently influence the analysis of the related trends?
• What would be the forecasted patient pool of trichomoniasis in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
• Among EU4 and the UK, which country will have the highest number of patients during the forecast period (2025–2034)?
• How many companies are currently developing therapies for the treatment of trichomoniasis?

Reasons to buy

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Trichomoniasis Market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years
• To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of current treatment in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Detailed analysis and ranking of class-wise potential current therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
• To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.